Monalizumab, a humanized immunoglobulin G (IgG) 4, targets NKG2A receptors and inhibits their interaction with HLA-E-expressing cancer cells and enhances degranulation and IFN-γ production by NKG2A + NK cells. This evidence concerns the gene IFNG and cancer.